Qiagen NV Share Price Nasdaq
Stocks
NL0000240000
Biotechnology & Medical Research
| Market Cap | 8.66B 7.5B 7.09B 6.42B 12.05B 831B 12.14B 84.65B 32.57B 421B 32.53B 31.81B 1,343B | P/E 2026 * |
21.7x | P/E 2027 * | 18.9x |
|---|---|---|---|---|---|
| Enterprise Value | 9.32B 8.08B 7.64B 6.91B 12.98B 894B 13.07B 91.13B 35.06B 453B 35.02B 34.24B 1,446B | EV / Sales 2026 * |
4.36x | EV / Sales 2027 * | 3.95x |
| Free-Float |
99.37% | Yield 2026 * |
0.32% | Yield 2027 * | 0.44% |
Last Transcript: Qiagen NV
| 1 day | -2.28% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jonathan Pratt
CEO | Chief Executive Officer | 56 | 31/08/2026 |
Roland Sackers
DFI | Director of Finance/CFO | 58 | 31/12/2003 |
Antonio Santos
COO | Chief Operating Officer | - | 31/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 77 | 31/05/2011 | |
Toralf Haag
BRD | Director/Board Member | 60 | 07/01/2021 |
Eva Pisa
BRD | Director/Board Member | 72 | 22/06/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.28% | -4.05% | - | - | 8.66B | |
| +0.56% | -4.17% | -1.90% | +9.79% | 45.63B | |
| -0.12% | -2.46% | +340.09% | +529.37% | 43.96B | |
| +1.51% | +0.71% | +44.04% | +26.63% | 43.73B | |
| -2.07% | -3.28% | +6.83% | +74.56% | 40.23B | |
| -0.73% | -4.72% | +8.55% | +37.89% | 31.86B | |
| -9.49% | -11.38% | - | - | 17.4B | |
| +4.21% | +4.94% | +26.46% | +121.58% | 16.62B | |
| +1.83% | +2.63% | +15.14% | +33.31% | 14.46B | |
| -0.08% | -5.41% | +78.48% | +31.34% | 13.04B | |
| Average | -0.68% | -1.81% | +64.71% | +108.06% | 29.66B | |
| Weighted average by Cap. | -0.42% | -2.09% | +76.22% | +128.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.14B 1.85B 1.75B 1.58B 2.97B 205B 3B 20.89B 8.04B 104B 8.03B 7.85B 331B | 2.24B 1.94B 1.84B 1.66B 3.12B 215B 3.15B 21.94B 8.44B 109B 8.43B 8.25B 348B |
| Net income | 397M 344M 325M 294M 552M 38.08B 557M 3.88B 1.49B 19.31B 1.49B 1.46B 61.58B | 478M 414M 392M 355M 666M 45.89B 671M 4.68B 1.8B 23.27B 1.8B 1.76B 74.21B |
| Net Debt | 663M 574M 543M 491M 922M 63.55B 929M 6.48B 2.49B 32.22B 2.49B 2.43B 103B | 214M 185M 175M 159M 298M 20.53B 300M 2.09B 805M 10.41B 804M 786M 33.2B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
